[Surgery for pancreatic adenocarcinoma: from established facts to changes in strategy?]

Pancreatic adenocarcinoma is still an aggressive disease with low survival. Apparently little changes have been made during the last years in the management of this disease, but knowledge and practices are evolving in many fields. Better understanding of the particular biology and genetics of this tumor will probably lead to more efficient targeted therapy. Surgical management with standardized "Enhanced Recovery After Surgery, ERAS" program diminishes postoperative medical morbidity, hospital length of stay and costs. Oncological treatment with more efficient chemotherapy is promising, with the emergence of strategy to perform more neoadjuvant treatments.